ANI Pharmaceuticals, Inc. (ANIP) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 7 Buy, 3 Hold.
The consensus price target is $107.00 (low: $90.00, high: $124.00), representing an upside of 36.7% from the current price $78.29.
Analysts estimate Earnings Per Share (EPS) of $5.01 and revenue of $0.60B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.87 vs est $5.01 (missed -117.4%). 2025: actual $3.50 vs est $7.54 (missed -53.6%). Analyst accuracy: 0%.
ANIP Stock — 12-Month Price Forecast
$107.00
▲ +36.67% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for ANI Pharmaceuticals, Inc., the average price target is $107.00, with a high forecast of $124.00, and a low forecast of $90.00.
The average price target represents a +36.67% change from the last price of $78.29.
Highest Price Target
$124.00
Average Price Target
$107.00
Lowest Price Target
$90.00
ANIP Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to ANI Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ANIP
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.87
vs Est $5.01
▼ 675.5% off
2025
Actual $3.50
vs Est $7.54
▼ 115.3% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — ANIP
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.614B
vs Est $0.599B
▲ 2.5% off
2025
Actual $0.883B
vs Est $0.867B
▲ 1.8% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
